Multiple Sclerosis: Therapy

Myelin Biology and Disorders

Volumn 2, Issue , 2004, Pages 791-806

  Antel, Jack ^a   Bar Or, Amit ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2142748072     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012439510-7/50086-3     Document Type: Chapter

References (82)

1. Anderton S., Burkhart C., Metzler B., Wraith D. Mechanisms of central and peripheral T-cell tolerance: lessons from experimental models of multiple sclerosis. Immunol. Rev. 1999, 169:123-137.
2. Antel J.P., Bar-Or A. Multiple sclerosis. Conn's Current Therapy 1-1-2003, 55th., W. B. Saunders Company, New York. R.E. Rakel, E.T. Bope (Eds.).
3. Becher B., Prat A., Antel J.P. Brain-immune connection: Immuno-regulatory properties of CNS-resident cells. Glia 2-15-2000, 29(4):293-304.
4. Beck R.W., Cleary P.A., Trobe J.D., Kaufman D.I., Kupersmith M.J., Paty D.W., Brown C.H. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N. Engl. J. Med. 12-9-1993, 329(24):1764-1769. The Optic Neuritis Study Group.
5. Bertolotto A., Malucchi S., Sala A., Orefice G., Carrieri P.B., Capobianco M., Milano E., Melis F., Giordana M.T. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J. Neurol. Neurosurg. Psychiatry 2002, 73(2):148-153.
6. Bieganowska K.D., Ausubel L.J., Modabber Y., Slovik E., Messersmith W., Hafler D.A. Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease. J. Exp. Med. 5-5-1997, 185(9):1585-1594.
7. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., Gran B., Eaton J., Antel J., Frank J.A., McFarland H.F., Martin R. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000, 6(10):1167-1175.
8. Brex P.A., Ciccarelli O., O'Riordan J.I., Sailer M., Thompson A.J., Miller D.H. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. 1-17-2002, 346(3):158-164.
9. Cashman N.R., Trojan D.A. Correlation of electrophysiology with pathology, pathogenesis, and anticholinesterase therapy in post-polio syndrome. Ann. N. Y. Acad. Sci. 5-25-1995, 753:138-150.
10. Charcot J.M. Lectures on diseases of the nervous system 1877, 158-222. translated by G. Sigerson, The New Sydenham Society.
11. Chari D.M., Blakemore W.F. New insights into remeyelination failure in multiple sclerosis: Implications for glial cell transplantation. Mult. Scler. 2002, 8(4):271-277.
12. Clanet M., Raduc E.W., Kappos L., Hartung H.P., Hohlfeld R., Sandberg-Wollheim M., Kooijmans-Coutinho M.F., Tsao E.C., Sandrock A.W. A randomized, double blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. J. Neurol. 2002, 59(10):1507-1517.
13. Coles A.J. Neutralising antibodies to the beta interferons. J. Neurol. Neurosurg. Psychiatry 2002, 73(2):110-111.
14. Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernandez O., Hartung H., Seeldrayers P., Sorensen P.S., Rovaris M., Martinelli V., Hommes O.R. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001, 357:1576-1582.
15. Comi G., Filippi M., Wolinsky J.S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann. Neurol. 2001, 49(3):290-297. European/Canadian Glatiramer Acetate Study Group.
16. Edan G., Miller D., Clanet M., Confavreux C., Lyon-Caen O., Lubetzki C., Brochet B., Berry I., Rolland Y., Froment J.C., Cabanis E., Iba-Zizen M.T., Gandon J.M., Lai H.M., Moseley I., Sabouraud O. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry 1997, 62(2):112-118.
17. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 11-7-1998, 352(9139):1491-1497. European Study Group on Interferon Beta-1b in Secondary Progressive MS.
18. Fernandez O., Guerrero M., Mayorga C., Munoz L., Lean A., Luque G., Hervas M., Fernandez V., Capdevila A., De Ramon E. Combination therapy with interferon Beta-1b and azathioprine in secondary progressive multiple sclerosis: A two-year pilot study. J. Neurol. 2002, 249(8):1058-1062.
19. Goodin D.S., Frohman E.M., Garmany G.P., Halper J., Likosky W.H., Lublin F.D., Silberberg D.H., Stuart W.H., van den, Noort S. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 1-22-2002, 58(2):169-178.
20. Goodkin D. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology 2000, 54:2352. the North American Study Group on Interferon beta-1b in Secondary Progressive MS.
21. Goodkin D.E., Rudick R.A., VanderBrug, Medendorp S., Daughtry M.M., Schwetz K.M., Fischer J., Van Dyke C. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann. Neurol. 1995, 37(1):30-40.
22. Gusev E., Boiko A., Bikova O., Maslova O., Guseva M., Boiko S., Vorobeichik G., Paty D. The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clin. Neurol. Neurosurg. 2002, 104(3):203-207.
23. Hauser S.L., Dawson D.M., Lehrich J.R., Beal M.F., Kevy S.V., Propper R.D., Mills J.A., Weiner H.L. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N. Engl. J. Med. 1-27-1983, 308(4):173-180.
24. Hoeber Paul B. Association for Research in Nervous and Mental Disease: Multiple Sclerosis 1922, (disseminated sclerosis). [1], New York.
25. Interferon Beta-1b Is Effective in Relapsing-Remitting Multiple Sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43(4):655-661. The IFNB Multiple Sclerosis Study Group.
26. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., Simonian N.A., Slasor P.J., Sandrock A.W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N. Engl. J. Med. 9-28-2000, 343(13):898-904. CHAMPS Study Group.
27. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., Alam J.J., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer F.E., Priore R.L., Pullicino P.M., Scherokman B.J., Whitham R.H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 1996, 39(3):285-294. The Multiple Sclerosis Collaborative Research Group (MSCRG).
28. Kappos L., Comi G., Panitch H., Oger J., Antel J., Conlon P., Steinman L. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat. Med. 2000, 6(10):1176-1182. The Altered Peptide Ligand in Relapsing MS Study Group.
29. Kaufman M., Gaydos C.A., Sriram S., Boman J., Tondella M.L., Norton H.J. Is Chiamydia pneumoniae found in spinal fluid samples from multiple sclerosis patients? Conflicting results. Mult. Scler. 2002, 8(4):289-294.
30. Kohm A.P., Carpentier P.A., Anger H.A., Miller S.D. Cutting Edge: CD4(+)CD25(+) Regulatory T Cells Suppress Antigen-Specific Autoreactive Immune Responses and Central Nervous System Inflammation During Active Experimental Autoimmune Encephalomyelitis. J. Immunol. 11-1-2002, 169(9):4712-4716.
31. Laman J.D., Maassen C.B., Schellekens M.M., Visser L., Kap M., de Jong E., van Puijenbroek M., van Stipdonk M.J., van Meurs M., Schwarzler C., Gunthert U. Therapy with antibodies against CD40L (CD154) and CD44-variant isoforms reduces experimental autoimmune encephalomyelitis induced by a proteolipid protein peptide. Mult. Scler. 1998, 4(3):147-153.
32. Lang H.L., Jacobsen H., Ikemizu S., Andersson C., Harlos K., Madsen L., Hjorth P., Sondergaard L., Svejaard A., Wucherpfennig K., Stuart D.I., Bell J.I., Jones E.Y., Fugger L. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 2002, 3(10):940-943.
33. Li D.K., Zhao G.J., Paty D.W. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 6-12-2001, 56(11):1505-1513.
34. McAlpine D. The benign form of multiple sclerosis. a study based on 241 cases seen within 3 years of onset and followed up until the 10th year or more of the disease. Brain 1961, 84:186-203.
35. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50(1):121-127.
36. Miller D.H., Khan O.A., Sheremata W.A., Blumbardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., O'Connor P.W. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2003, 348:15-23.
37. Miller R.G., Mitchell J.D., Lyon M., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane. Database. Syst. Rev. 2002, (2). CD001447.
38. Miller S.D., Katz-Levy Y., Neville K.L., Vanderlugt C.L. Virus-induced autoimmunity: Epitope spreading to myelin autoepitopes in Theiler's virus infection of the central nervous system. Adv. Virus Res. 2001, 56:199-217.
39. Moore F.G., Wolfson C. Human herpes virus 6 and multiple sclerosis. Acta Neurol. Scand. 2002, 106(2):63-83.
40. Murray T.J., Burks J.S., Johnson K.P. Multiple Sclerosis: Diagnosis, Medical Management, and Rehabilitation 2000, 1-34. (1), Demos Medical Publishing, London.
41. Murthy S.N., Faden H.S., Cohen M.E., Bakshi R. Acute disseminated encephalomyelitis in children. Pediatrics 2002, 110:e21. (2 Pt 1).
42. Narayanan S., De Stefano N., Francis G.S., Arnaoutelis R., Caramanos Z., Collins D.L., Pelletier D., Arnason B.G.W., Antel J.P., Arnold D.L. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J. Neurol. 2001, 248(11):979-986.
43. National Multiple Sclerosis Society Therapeutic Claims in Multiple Sclerosis 1982, New York. 1st. ed.
44. Neuhaus O., Farina C., Wekerle H., Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 3-27-2001, 56(6):702-708.
45. Niehaus A., Shi J., Grzenkowski M., Diers-Fenger M., Archelos J., Hartung H.P., Toyka K., Bruck W., Trotter J. Patients with active relapsing-remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: implications for remyelination. Ann. Neurol. 2000, 48(3):362-371.
46. Noseworthy J.H., O'Brien P.C., Petterson T.M., Weis J., Stevens L., Peterson W.K., Sneve D., Cross S.A., Leavitt J.A., Auger R.G., Weinshenker B.G., Dodick D.W., Wingerchuk D.M., Rodriguez M. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 6-12-2001, 56(11):1514-1522.
47. Noseworthy J.H., Vandervoort M.K., Penman M., Ebers G., Shumak K., Seland T.P., Roberts R., Yetisir E., Gent M., Taylor D.W. Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet 6-22-1991, 337(8756):1540-1541.
48. Owens T., Tran E., Hassan-Zahraee M., Krakowski M. Immune cell entry to the CNS-a focus for immunoregulation of EAE. Res. Immunol. 1998, 149(9):781-789.
49. Owens T., Wekerle H., Antel J. Genetic models for CNS inflammation. Nat. Med. 2001, 7(2):161-166.
50. Palace J., Rothwell P. New treatments and azathioprine in multiple sclerosis. Lancet 7-26-1997, 350(9073):261.
51. Panitch H., Goodin D.S., Francis G., Chang P., Coyle P.K., O'Connor P., Monaghan E., Li D., Weinsberkar B. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the evidence trial. Neurology 2002, 59(10):1496-1506.
52. Paolillo A., Coles A.J., Molyneux P.D., Gawne-Cain M., MacManus D., Barker G.J., Compston D.A., Miller D.H. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 9-11-1999, 53(4):751-757.
53. Paty D., Ebers G.C. Multiple Sclerosis 1997, F. A. Davis Company, New York.
54. Pelfrey C.M., Rudick R.A., Cotleur A.C., Lee J.C., Tary-Lehmann M., Lehmann P.V. Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J. Immunol. 8-1-2000, 165(3):1641-1651.
55. Pozzilli C., Antonini G., Bagnato F., Mainero C., Tomassini V., Onesti E., Fantozzi R., Galgani S., Pasqualetti P., Millefiorini E., Spadaro M., Dahlke F., Gasperini C. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: A randomized trial in multiple sclerosis. J. Neurol. 2002, 249(1):50-56.
56. Prat A., Biernacki K., Lavoie J.F., Poirier J., Duquette P., Antel J.P. Migration of multiple sclerosis lymphocytes through brain endothelium. Arch. Neurol. 2002, 59(3):391-397.
57. Prat A., Biernacki K., Wosik K., Antel J.P. Glial cell influence on the human blood-brain barrier. Glia 2001, 36(2):145-155.
58. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 11-7-1998, 352(9139):1498-1504. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
59. Racke M.K., Ratts R.B., Arredondo L., Perrin P.J., Lovett-Racke A. The role of costimulation in autoimmune demyelination. J. Neuroimmunol. 7-24-2000, 107(2):205-215.
60. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology 6-12-2001, 56(11):1496-1504.
61. Reddy H., Narayanan S., Arnoutelis R., Jenkinson M., Antel J., Matthews P.M., Arnold D.L. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain 2000, 123:2314-2320. (Pt. 11).
62. Rice G.P., Filippi M., Comi G. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Neurology 3-14-2000, 54(5):1145-1155. Cladribine MRI Study Group.
63. Robinson W.H., Garren H., Utz P.J., Steinman L. Millennium Award. Proteomics for the development of DNA tolerizing vaccines to treat autoimmune disease. Clin. Immunol. 2002, 103(1):7-12.
64. Santambrogio L., Belyanskaya S.L., Fischer F.R., Cipriani B., Brosnan C.F., Ricciardi-Castagnoli P., Stern L.J., Strominger J.L., Riese R. Developmental plasticity of CNS microglia. Proc. Natl. Acad. Sci. USA 5-22-2001, 98:6295-6300. (11).
65. Smith D.R., Olek M.J., Balashov K.E., Khoury S.J., Hafler D.A., Weiner H.L. Principles of immunotherapy. Clinical Neuroimmunology 1998, 92-104. (7), Blackwell Science, Philadelphia. J.P. Antel, G. Birnbaum, H.-P. Hartung (Eds.).
66. Sung M.H., Zhao Y., Martin R., Simon R. T-cell epitope prediction with combinatorial peptide libraries. J. Comput. Biol. 2002, 9(3):527-539.
67. Swamy H.S., Shankar S.K., Chandra P.S., Aroor S.R., Krishna A.S., Perumal V.G. Neurological complications due to beta-propiolactone (BPL)-inactivated antirabies vaccination. Clinical, electrophysiological and therapeutic aspects. J. Neurol. Sci. 1984, 63(1):111-128.
68. Talbot P.J., Arnold D., Antel J.P. Virus-induced autoimmune reactions in the CNS. Curr. Top. Microbiol. Immunol. 2001, 253:247-271.
69. Therapeutic Claims in Multiple Sclerosis 1992, Demo Publications, Oxford. 3rd ed. W. Sibley (Ed.).
70. Tourbah A., Gout O., Liblau R., Lyon-Caen O., Bougniot C., Iba-Zizen M.T., Cabanis E.A. Encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS?. Neurology 7-22-1999, 53(2):396-401.
71. Tubridy N., Behan P.O., Capildeo R., Chaudhuri A., Forbes R., Hawkins C.P., Hughes R.A., Palace J., Sharrack B., Swingler R., Young C., Moseley I.F., MacManus D.G., Donoghue S., Miller D.H. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. Neurology 8-11-1999, 53(3):466-472. The UK Antegren Study Group.
72. Tuohy V.K., Kinkel R.P. Epitope spreading: a mechanism for progression of autoimmune disease. Arch. Immunol. Ther. Exp. (Warsz). 2000, 48(5):347-351.
73. van de Wyngaert F.A., Beguin C., D'Hooghe M.B., Dooms G., Lissoir F., Carton H., Sindic C.J. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol. Belg. 2001, 101(4):210-216.
74. Vandenbark A.A., Chou Y.K., Whitham R., Mass M., Buenafe A., Liefeld D., Kavanagh D., Cooper S., Hashim G.A., Offner H. Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial. Nat. Med. 1996, 2(10):1109-1115.
75. Waxman S.G. Acquired channelopathies in nerve injury and MS. Neurology 6-26-2001, 56(12):1621-1627.
76. Weinshenker B.G., O'Brien P.C., Petterson T.M., Noseworthy J.H., Lucchinetti C.F., Dodick D.W., Pineda A.A., Stevens L.N., Rodriguez M. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann. Neurol. 1999, 46(6):878-886.
77. Wiendl H., Hohlfeld R. Therapeutic approaches in multiple sclerosis: Lessons from failed and interrupted treatment trials. BioDrugs 2002, 16(3):183-200.
78. Wosik K., Antel J., Kuhlmann T., Bruck W., Massie B., Nalbantoglu J. Oligodendrocyte injury in multiple sclerosis: a role for p53. J. Neurochem. 2003, 85(3):635-644.
79. Wucherpfennig K.W. Infectious triggers for inflammatory neurological diseases. Nat. Med. 2002, 8(5):455-457.
80. Zhang J.Z., Rivera V.M., Tejada-Simon M.V., Yang D., Hong J., Li S., Haykal H., Killian J., Zang Y.C. T cell vaccination in multiple sclerosis: Results of a preliminary study. J. Neurol. 2002, 249(2):212-218.
81. Zhao G.J., Li D.K., Wolinsky J.S., Koopmans R.A., Mietlowski W., Redekop W.K., Riddehough A., Cover K., Paty D.W. Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. J. Neuroimaging 1997, 7(1):1-7. The MS Study Group.
82. Zivadinov R., Rudick R.A., De Masi R., Nasuelli D., Ukmar M., Pozzi-Mucelli R.S., Grop A., Cazzato G., Zorzon M. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 10-9-2001, 57(7):1239-1247.